veltuzumab veltuzumab veltuzumab is a monoclonal antibody (targeted at cd20) which is being investigated for the treatment of non-hodgkin's lymphoma. as of december 2011, it is undergoing phase i/ii clinical trials. when used with milatuzumab it showed activity. veltuzumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetcd20clinical dataatc codenoneidentifierscas number728917-18-8 nchemspidernoneuniibpd4dgq314chemical and physical dataformulac6458h9918n1706o2026s46molar mass145349.06 g·mol−1 ny (what is this?) (verify) this drug was developed by immunomedics, inc. and was originally known as immu-106. in august 2015 the us fda granted it orphan drug status for immune thrombocytopenia (itp). a phase ii trial is planned to run for 5 years.